Jefferies Financial Group Inc. Sells 3,297,945 Shares of Integer Holdings Corporation (NYSE:ITGR)

Jefferies Financial Group Inc. trimmed its stake in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) by 98.9% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 37,706 shares of the medical equipment provider's stock after selling 3,297,945 shares during the quarter. Jefferies Financial Group Inc. owned about 0.11% of Integer worth $4,450,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. TD Private Client Wealth LLC raised its holdings in shares of Integer by 5.8% during the 1st quarter. TD Private Client Wealth LLC now owns 1,524 shares of the medical equipment provider's stock worth $180,000 after buying an additional 83 shares in the last quarter. HighPoint Advisor Group LLC increased its position in Integer by 6.4% during the 4th quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider's stock worth $234,000 after purchasing an additional 101 shares in the last quarter. Xponance Inc. boosted its position in Integer by 5.1% in the first quarter. Xponance Inc. now owns 2,518 shares of the medical equipment provider's stock valued at $297,000 after buying an additional 122 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Integer by 73.1% during the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after buying an additional 125 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust increased its holdings in shares of Integer by 0.8% during the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 19,867 shares of the medical equipment provider's stock worth $2,633,000 after buying an additional 152 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.

Integer Price Performance

ITGR stock opened at $106.52 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. The business has a 50-day simple moving average of $117.65 and a two-hundred day simple moving average of $122.80. The company has a market capitalization of $3.73 billion, a P/E ratio of 46.93, a price-to-earnings-growth ratio of 0.86 and a beta of 1.02. Integer Holdings Corporation has a 52-week low of $104.93 and a 52-week high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The company had revenue of $476.00 million during the quarter, compared to the consensus estimate of $464.37 million. During the same quarter in the prior year, the business earned $1.30 EPS. The firm's revenue for the quarter was up 11.4% compared to the same quarter last year. Research analysts expect that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on ITGR. Citigroup raised Integer from a "hold" rating to a "strong-buy" rating and upped their target price for the stock from $133.00 to $140.00 in a report on Thursday, May 22nd. Raymond James Financial dropped their price target on shares of Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a research report on Friday, July 25th. Benchmark decreased their price objective on shares of Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Truist Financial dropped their target price on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a report on Friday, July 25th. Finally, Wall Street Zen raised Integer from a "sell" rating to a "hold" rating in a research note on Monday, May 19th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $140.25.

Insider Buying and Selling at Integer

In other Integer news, Director Donald J. Spence sold 14,739 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total value of $1,774,280.82. Following the completion of the sale, the director directly owned 18,781 shares of the company's stock, valued at approximately $2,260,856.78. This represents a 43.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Martin C. Maxwell sold 8,720 shares of Integer stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the transaction, the director directly owned 22,170 shares in the company, valued at approximately $2,672,815.20. This represents a 28.23% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.16% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.